1-15 of 109
IL-17A Inhibition and Neuroendocrine Signaling in Psoriasis
DermConsultIL-17A Inhibition and Neuroendocrine Signaling in Psoriasis
IL-17A Inhibition and the Stress Response in Psoriasis
AudioAbstractsIL-17A Inhibition and the Stress Response in Psoriasis
Obesity and Asthma: Intersecting Pathways and Real-World Impacts
Clinician's RoundtableObesity and Asthma: Intersecting Pathways and Real-World Impacts
MASLD and MASH in Focus: Clinical Priorities and Promising Pathways
Clinician's RoundtableMASLD and MASH in Focus: Clinical Priorities and Promising Pathways
The Hidden Respiratory Burden of Obesity: Understanding the Clinical Consequences
Clinician's RoundtableThe Hidden Respiratory Burden of Obesity: Understanding the Clinical Consequences
Understanding the Growing Impacts of Obesity on Patient Outcomes and Care Delivery
Clinician's RoundtableUnderstanding the Growing Impacts of Obesity on Patient Outcomes and Care Delivery
- advertisement
MASLD Explained: A Modern Framework for a Multisystem Condition
Clinician's RoundtableMASLD Explained: A Modern Framework for a Multisystem Condition
Unveiling the Role of Obesity in MASLD Progression
Clinician's RoundtableUnveiling the Role of Obesity in MASLD Progression
New Insights into VKD: Exploring Maternal Obesity and Neonatal Vitamin K Status
Clinician's RoundtableNew Insights into VKD: Exploring Maternal Obesity and Neonatal Vitamin K Status
From Gut Microbe to Metabolic Modulator: The Potential Role of R. hominis in Obesity
Clinician's RoundtableFrom Gut Microbe to Metabolic Modulator: The Potential Role of R. hominis in Obesity
Understanding Thyroid Hormone Dynamics After COVID-19 Infection
Clinician's RoundtableUnderstanding Thyroid Hormone Dynamics After COVID-19 Infection
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart MattersRethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
- advertisement
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
NephrologyFinerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
NephrologyImplications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
NephrologyNew Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
